{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:55:07Z","timestamp":1780372507395,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.therap.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:08:26Z","timestamp":1593256106000},"page":"335-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review"],"prefix":"10.1016","volume":"75","author":[{"given":"Lucile","family":"Grange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Guilpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-1469","authenticated-orcid":false,"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.therap.2020.06.013_bib0375","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.therap.2020.06.013_bib0380","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.therap.2020.06.013_bib0385","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.therap.2020.06.013_bib0390","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med Infect Dis"},{"issue":"10223","key":"10.1016\/j.therap.2020.06.013_bib0395","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2020.06.013_bib0400","series-title":"WHO coronavirus disease (COVID-19) dashboard","year":"2020"},{"issue":"3","key":"10.1016\/j.therap.2020.06.013_bib0405","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"issue":"2","key":"10.1016\/j.therap.2020.06.013_bib0410","first-page":"158","article-title":"Rheumatoid arthritis associated interstitial lung disease: a review","volume":"74","author":"Assayag","year":"2014","journal-title":"Medicina (Mex)"},{"issue":"2","key":"10.1016\/j.therap.2020.06.013_bib0415","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1685537","article-title":"Pulmonary complications of systemic lupus erythematosus","volume":"40","author":"Hannah","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"10103","key":"10.1016\/j.therap.2020.06.013_bib0420","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2020.06.013_bib0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.04.021","article-title":"Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis","author":"Zheng","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.therap.2020.06.013_bib0430","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/ard.2010.142133","article-title":"Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives","volume":"70","author":"Kitas","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0435","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: what's next?","author":"Scavone","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.therap.2020.06.013_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0445","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.06.013_bib0450","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2016638","article-title":"A Randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19","author":"Boulware","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.06.013_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.010","article-title":"Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence","author":"Roustit","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.06.013_bib0460","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol Orlando Fla"},{"issue":"2","key":"10.1016\/j.therap.2020.06.013_bib0465","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.therap.2020.06.013_bib0470","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.therap.2020.06.013_bib0475","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.therap.2020.06.013_bib0480","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/annrheumdis-2020-217322","article-title":"Are my patients with rheumatic diseases at higher risk of COVID-19?","volume":"79","author":"Figueroa-Parra","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.therap.2020.06.013_bib0485","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.therap.2020.06.013_bib0490","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/ard.2006.057265","article-title":"Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis","volume":"66","author":"Franklin","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0495","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26050","article-title":"Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis","author":"Tian","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.therap.2020.06.013_bib0500","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.therap.2020.06.013_bib0505","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.05.008","article-title":"Cardiovascular disease in systemic lupus erythematosus: a comprehensive update","volume":"82","author":"Giannelou","year":"2017","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.therap.2020.06.013_bib0515","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/ijms18102211","article-title":"Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment","volume":"18","author":"Hu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.therap.2020.06.013_bib0520","article-title":"OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients","author":"Williamson","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.therap.2020.06.013_bib0525","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatol Oxf Engl"},{"issue":"12","key":"10.1016\/j.therap.2020.06.013_bib0530","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.therap.2020.06.013_bib0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102575","article-title":"SARS-CoV-2 infection among patients with systemic autoimmune diseases","volume":"19","author":"Emmi","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.therap.2020.06.013_bib0540","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.200507","article-title":"Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis","author":"Favalli","year":"2020","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.therap.2020.06.013_bib0545","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0550","article-title":"COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs","author":"Conticini","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.therap.2020.06.013_bib0555","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/fcp.12564","article-title":"Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic","volume":"34","author":"Larrouquere","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.therap.2020.06.013_bib0560","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/jcm8060786","article-title":"Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients","volume":"8","author":"Voiriot","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.therap.2020.06.013_bib0565","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0570","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3332\/ecancer.2020.1023","article-title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.therap.2020.06.013_bib0575","doi-asserted-by":"crossref","first-page":"m1185","DOI":"10.1136\/bmj.m1185","article-title":"Non-steroidal anti-inflammatory drugs and COVID-19","volume":"368","author":"Little","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.06.013_bib0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.003","article-title":"Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection","author":"Micallef","year":"2020","journal-title":"Therapies"},{"issue":"3","key":"10.1016\/j.therap.2020.06.013_bib0585","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.therap.2020.06.013_bib0590","first-page":"395","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"15","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.therap.2020.06.013_bib0595","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41375-020-0848-3","article-title":"Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis","volume":"34","author":"Li","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.therap.2020.06.013_bib0600","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.06.013_bib0605","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijid.2020.03.047","article-title":"Risk-adapted treatment strategy for COVID-19 patients","volume":"94","author":"Zheng","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0610","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv"},{"issue":"9","key":"10.1016\/j.therap.2020.06.013_bib0615","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/CM9.0000000000000791","article-title":"Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial","volume":"133","author":"Qin","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.therap.2020.06.013_bib0620","series-title":"Clinical management of COVID-19","author":"World Health Organization","year":"2020"},{"issue":"1","key":"10.1016\/j.therap.2020.06.013_bib0625","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jcm8010015","article-title":"Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2018","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.therap.2020.06.013_bib0630","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0002-9343(91)80008-A","article-title":"Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate","volume":"90","author":"Antonelli","year":"1991","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.therap.2020.06.013_bib0635","doi-asserted-by":"crossref","first-page":"e014032","DOI":"10.1136\/bmjopen-2016-014032","article-title":"Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.therap.2020.06.013_bib0640","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"10.1016\/j.therap.2020.06.013_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.02.007","article-title":"Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway","volume":"128","author":"Wang","year":"2007","journal-title":"Virus Res"},{"issue":"7","key":"10.1016\/j.therap.2020.06.013_bib0650","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"issue":"20","key":"10.1016\/j.therap.2020.06.013_bib0655","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.therap.2020.06.013_bib0660","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"issue":"10","key":"10.1016\/j.therap.2020.06.013_bib0665","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"10223","key":"10.1016\/j.therap.2020.06.013_bib0670","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2020.06.013_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","author":"Cantini","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.therap.2020.06.013_bib0680","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2020.04.097","article-title":"Reply: Ccalm before the storm: understanding the role of janus kinase inhibitors in COVID-19","volume":"83","author":"Peterson","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2020.06.013_bib0685","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16896","article-title":"Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature","author":"Tepasse","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.therap.2020.06.013_bib0690","first-page":"1","article-title":"Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis","volume":"20","author":"Devogelaere","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.therap.2020.06.013_bib0695","article-title":"Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab","author":"Avouac","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0700","article-title":"Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia","author":"Guilpain","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.therap.2020.06.013_bib0705","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.therap.2020.06.013_bib0710","article-title":"Response to: \u201cSevere COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab\u201d by Avouac et al.","author":"Guilpain","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.therap.2020.06.013_bib0715","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.therap.2020.06.013_bib0720","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.therap.2020.06.013_bib0725","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/annrheumdis-2020-217566","article-title":"Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0730","article-title":"Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak","author":"Holubar","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0735","article-title":"Patients with lupus with COVID-19: university of Michigan experience","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2020.06.013_bib0740","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217690","article-title":"Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19","author":"Konig","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:58Z","timestamp":1758567238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0040595720301189"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.013","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}